Tyrosine capsid-mutant AAV vectors for gene delivery to the canine retina from a subretinal or intravitreal approach

Gene Therapy

Volumn 21, Issue 1, 2014, Pages 96-105

  Mowat, F M ^a   Gornik, K R ^a   Dinculescu, A ^b   Boye, S L ^b   Hauswirth, W W ^b   Petersen Jones, S M ^a   Bartoe, J T ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

canine; capsid mutant; rAAV; retina

Indexed keywords

ADENOVIRUS VECTOR; BETA ACTIN; CALRETININ; GREEN FLUORESCENT PROTEIN; TYROSINE;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEAGLE; CANINE MODEL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOG; FEMALE; GENE TARGETING; IMMUNOHISTOCHEMISTRY; INJECTION SITE; INTRAVITREAL DRUG ADMINISTRATION; MALE; NERVE CELL; NONHUMAN; OPTIC NERVE; PHOTORECEPTOR; PRIORITY JOURNAL; PROMOTER REGION; RETINA; RETINA BLOOD VESSEL; RETINA CELL; RETINITIS PIGMENTOSA; SUBRETINAL INJECTION; TROPISM; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS MUTANT;

ADENO-ASSOCIATED VIRUS; ANIMALIA; CANIS FAMILIARIS; MIRIDAE; RODENTIA;

AMINO ACID SUBSTITUTION; ANIMALS; CAPSID; DEPENDOVIRUS; DOGS; FEMALE; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAOCULAR; MALE; MUTATION; RECOMBINANT PROTEINS; RETINA; TRANSDUCTION, GENETIC; TYROSINE; VIRAL TROPISM;

EID: 84891736963     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2013.64     Document Type: Article

References (63)

1. Jacobson SG, Cideciyan AV, Ratnakaram R, Heon E, Schwartz SB, Roman AJ et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 2012; 130: 9-24.
2. Simonelli F, Maguire AM, Testa F, Pierce EA, Mingozzi F, Bennicelli JL et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 2010; 18: 643-650.
3. Cideciyan AV, Hauswirth WW, Aleman TS, Kaushal S, Schwartz SB, Boye SL et al. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther 2009; 20: 999-1004.
4. Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008; 19: 979-990.
5. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008; 358: 2231-2239. (Pubitemid 351724452)
6. Maguire AM, Simonelli F, Pierce EA, Pugh Jr EN, Mingozzi F, Bennicelli J et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008; 358: 2240-2248. (Pubitemid 351724453)
7. Acland GM, Aguirre GD, Ray J, Zhang Q, Aleman TS, Cideciyan AV et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 2001; 28: 92-95. (Pubitemid 32405824)
8. Acland GM, Aguirre GD, Bennett J, Aleman TS, Cideciyan AV, Bennicelli J et al. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther 2005; 12: 1072-1082. (Pubitemid 41723041)
9. Le Meur G, Stieger K, Smith AJ, Weber M, Deschamps JY, Nivard D et al. Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Gene Therapy 2007; 14: 292-303. (Pubitemid 46231923)
10. Anasagasti A, Irigoyen C, Barandika O, Lopez de Munain A, Ruiz-Ederra J. Current mutation discovery approaches in Retinitis Pigmentosa. Vision Res 2012; 75: 117-129.
11. Komaromy AM, Alexander JJ, Rowlan JS, Garcia MM, Chiodo VA, Kaya A et al. Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet 2010; 19: 2581-2593.
12. Mowat FM, Bartoe JT, Bruewer A, Dinculescu A, Boye SL, Hauswirth WW et al. Evaluation of rod photoreceptor function and preservation following retinal gene therapy in the PDE6A mutant dog. ARVO Meeting Abstracts 2012; 53: 1928.
13. Petit L, Lheriteau E, Weber M, Le Meur G, Deschamps JY, Provost N et al. Restoration of vision in the pde6beta-deficient dog, a large animal model of rod-cone dystrophy. Mol Ther 2012; 20: 2019-2030.
14. Beltran WA, Cideciyan AV, Lewin AS, Iwabe S, Khanna H, Sumaroka A et al. Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. Proc Natl Acad Sci USA 2012; 109: 2132-2137.
15. Pennesi ME, Stover NB, Stone EM, Chiang PW, Weleber RG. Residual electroretinograms in young Leber congenital amaurosis patients with mutations of AIPL1. Invest Ophthalmol Vis Sci 2011; 52: 8166-8173.
16. Jacobson SG, Cideciyan AV, Aleman TS, Sumaroka A, Roman AJ, Swider M et al. Human retinal disease from AIPL1 gene mutations: foveal cone loss with minimal macular photoreceptors and rod function remaining. Invest Ophthalmol Vis Sci 2011; 52: 70-79.
17. Testa F, Surace EM, Rossi S, Marrocco E, Gargiulo A, Di Iorio V et al. Evaluation of Italian patients with leber congenital amaurosis due to AIPL1 mutations highlights the potential applicability of gene therapy. Invest Ophthalmol Vis Sci 2011; 52: 5618-5624.
18. Petersen-Jones SM, Entz DD, Sargan DR. cGMP phosphodiesterase-alpha mutation causes progressive retinal atrophy in the Cardigan Welsh corgi dog. Invest Ophthalmol Vis Sci 1999; 40: 1637-1644. (Pubitemid 29297134)
19. Tuntivanich N, Pittler SJ, Fischer AJ, Omar G, Kiupel M, Weber A et al. Characterization of a canine model of autosomal recessive retinitis pigmentosa due to a PDE6A mutation. Invest Ophthalmol Vis Sci 2009; 50: 801-813.
20. Sarra GM, Stephens C, Schlichtenbrede FC, Bainbridge JW, Thrasher AJ, Luthert PJ et al. Kinetics of transgene expression in mouse retina following sub-retinal injection of recombinant adeno-associated virus. Vision Res 2002; 42: 541-549. (Pubitemid 34169712)
21. Petersen-Jones SM, Bartoe JT, Fischer AJ, Scott M, Boye SL, Chiodo V et al. AAV retinal transduction in a large animal model species: comparison of a self-complementary AAV2/5 with a single-stranded AAV2/5 vector. Mol Vis 2009; 15: 1835-1842.
22. Natkunarajah M, Trittibach P, McIntosh J, Duran Y, Barker SE, Smith AJ et al. Assessment of ocular transduction using single-stranded and self-complementary recombinant adeno-associated virus serotype 2/8. Gene Therapy 2008; 15: 463-467. (Pubitemid 351331004)
23. Cook B, Lewis GP, Fisher SK, Adler R. Apoptotic photoreceptor degeneration in experimental retinal detachment. Invest Ophthalmol Vis Sci 1995; 36: 990-996.
24. Fisher SK, Lewis GP. Muller cell and neuronal remodeling in retinal detachment and reattachment and their potential consequences for visual recovery: a review and reconsideration of recent data. Vision Res 2003; 43: 887-897. (Pubitemid 36369129)
25. Fisher SK, Stone J, Rex TS, Linberg KA, Lewis GP. Experimental retinal detachment: a paradigm for understanding the effects of induced photoreceptor degeneration. Prog Brain Res 2001; 131: 679-698.
26. Igarashi T, Miyake K, Asakawa N, Miyake N, Shimada T, Takahashi H. Direct comparison of administration routes for AAV8-mediated ocular gene therapy. Curr Eye Res 2013; 38: 569-577.
27. Englander M, Chen TC, Paschalis EI, Miller JW, Kim IK. Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates. Br J Ophthalmol 2013; 97: 460-465.
28. Stieger K, Schroeder J, Provost N, Mendes-Madeira A, Belbellaa B, Le Meur G et al. Detection of intact rAAV particles up to 6 years after successful gene transfer in the retina of dogs and primates. Mol Ther 2009; 17: 516-523.
29. Auricchio A, Pseudotyped AAV. vectors for constitutive and regulated gene expression in the eye. Vision Res 2003; 43: 913-918. (Pubitemid 36369131)
30. Lebherz C, Maguire A, Tang W, Bennett J, Wilson JM, Novel AAV. serotypes for improved ocular gene transfer. J Gene Med 2008; 10: 375-382. (Pubitemid 351517093)
31. Boye SE, Boye SL, Lewin AS, Hauswirth WW. A comprehensive review of retinal gene therapy. Mol Ther 2013; 21: 509-519.
32. Zhong L, Zhao W, Wu J, Li B, Zolotukhin S, Govindasamy L et al. A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. Mol Ther 2007; 15: 1323-1330. (Pubitemid 46965329)
33. Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, Cooper M et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA 2008; 105: 7827-7832. (Pubitemid 351872723)
34. Petrs-Silva H, Dinculescu A, Li Q, Min SH, Chiodo V, Pang JJ et al. High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther 2009; 17: 463-471.
35. Petrs-Silva H, Dinculescu A, Li Q, Deng WT, Pang JJ, Min SH et al. Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011; 19: 293-301.
36. Pang JJ, Dai X, Boye SE, Barone I, Boye SL, Mao S et al. Long-term retinal function and structure rescue using capsid mutant AAV8 vector in the rd10 mouse, a model of recessive retinitis pigmentosa. Mol Ther 2011; 19: 234-242.
37. Ku CA, Chiodo VA, Boye SL, Goldberg AF, Li T, Hauswirth WW et al. Gene therapy using self-complementary Y733F capsid mutant AAV2/8 restores vision in a model of early onset Leber congenital amaurosis. Hum Mol Genet 2011; 20: 4569-4581.
38. Boye SL, Conlon T, Erger K, Ryals R, Neeley A, Cossette T et al. Long-term preservation of cone photoreceptors and restoration of cone function by gene therapy in the guanylate cyclase-1 knockout (GC1KO) mouse. Invest Ophthalmol Vis Sci 2011; 52: 7098-7108.
39. Dinculescu A, Estreicher J, Zenteno JC, Aleman TS, Schwartz SB, Huang WC et al. Gene therapy for retinitis pigmentosa caused by MFRP mutations: human phenotype and preliminary proof of concept. Hum Gene Ther 2012; 23: 367-376.
40. Deng WT, Dinculescu A, Li Q, Boye SL, Li J, Gorbatyuk MS et al. Tyrosine-mutant AAV8 delivery of human MERTK provides long-term retinal preservation in RCS rats. Invest Ophthalmol Vis Sci 2012; 53: 1895-1904.
41. Martino AT, Basner-Tschakarjan E, Markusic DM, Finn JD, Hinderer C, Zhou S et al. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8\+ T cells. Blood 2013; 121: 2224-2233.
42. Aslanidi GV, Rivers AE, Ortiz L, Song L, Ling C, Govindasamy L et al. Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold PLoS One 2013; 8: e59142.
43. Cideciyan AV, Jacobson SG, Beltran WA, Sumaroka A, Swider M, Iwabe S et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci USA 2013; 110: E517-E525.
44. Kay CN, Ryals RC, Aslanidi GV, Min SH, Ruan Q, Sun J et al. Targeting Photoreceptors via Intravitreal Delivery Using Novel, Capsid-Mutated AAV Vectors. PLoS One 2013; 8: e62097.
45. Garcia-Sanchez GA, Gil-Carrasco F, Roman JJ, Brooks DE, Alvarez-Clau A, Hosgood G et al. Measurement of retinal nerve fiber layer thickness in normal and glaucomatous Cocker Spaniels by scanning laser polarimetry. Vet Ophthalmol 2007; 10(Suppl 1): 78-87. (Pubitemid 350007148)
46. Hernandez-Merino E, Kecova H, Jacobson SJ, Hamouche KN, Nzokwe RN, Grozdanic SD. Spectral domain optical coherence tomography (SD-OCT) assessment of the healthy female canine retina and optic nerve. Vet Ophthalmol 2011; 14: 400-405.
47. Ferguson LR, Dominguez IiJM, Balaiya S, Grover S, Chalam KV. Retinal Thickness Normative Data in Wild-Type Mice Using Customized Miniature SD-OCT. PLoS One 2013; 8: e67265.
48. Dalkara D, Byrne LC, Klimczak RR, Visel M, Yin L, Merigan WH et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med 2013; 5: 189ra76.
49. Dalkara D, Kolstad KD, Caporale N, Visel M, Klimczak RR, Schaffer DV et al. Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol Ther 2009; 17: 2096-2102.
50. Kolstad KD, Dalkara D, Guerin K, Visel M, Hoffmann N, Schaffer DV et al. Changes in adeno-associated virus-mediated gene delivery in retinal degeneration. Hum Gene Ther 2010; 21: 571-578.
51. Heegaard S. Structure of the human vitreoretinal border region. Ophthalmologica 1994; 208: 82-91. (Pubitemid 24108935)
52. Matsumoto B, Blanks JC, Ryan SJ. Topographic variations in the rabbit and primate internal limiting membrane. Invest Ophthalmol Vis Sci 1984; 25: 71-82. (Pubitemid 14220990)
53. Wolter JR. Pores in the Internal Limiting Membrane of the Human Retina. Acta Ophthalmol 1964; 42: 971-974.
54. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431. (Pubitemid 44511557)
55. Bi A, Cui J, Ma YP, Olshevskaya E, Pu M, Dizhoor AM et al. Ectopic expression of a microbial-type rhodopsin restores visual responses in mice with photoreceptor degeneration. Neuron 2006; 50: 23-33.
56. Tomita H, Sugano E, Yawo H, Ishizuka T, Isago H, Narikawa S et al. Restoration of visual response in aged dystrophic RCS rats using AAV-mediated channelopsin-2 gene transfer. Invest Ophthalmol Vis Sci 2007; 48: 3821-3826. (Pubitemid 351261123)
57. Lin B, Koizumi A, Tanaka N, Panda S, Masland RH. Restoration of visual function in retinal degeneration mice by ectopic expression of melanopsin. Proc Natl Acad Sci USA 2008; 105: 16009-16014.
58. Zhang Y, Ivanova E, Bi A, Pan ZH. Ectopic expression of multiple microbial rhodopsins restores ON and OFF light responses in retinas with photoreceptor degeneration. J Neurosci 2009; 29: 9186-9196.
59. Doroudchi MM, Greenberg KP, Liu J, Silka KA, Boyden ES, Lockridge JA et al. Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness. Mol Ther 2011; 19: 1220-1229.
60. Bruewer AR, Mowat FM, Bartoe JT, Boye SL, Hauswirth WW, Petersen-Jones SM. Evaluation of lateral spread of transgene expression following subretinal AAV-mediated gene delivery in dogs. PLoS One 2013; 8: e60218.
61. Gearhart PM, Gearhart C, Thompson DA, Petersen-Jones SM. Improvement of visual performance with intravitreal administration of 9-cis-retinal in Rpe65-mutant dogs. Arch Ophthalmol 2010; 128: 1442-1448.
62. Mowat FM, Bartoe JT, Bruewer A, Smith AJ, Bainbridge JB, Ali RR et al. RPE65 gene therapy promotes survival of S-cones in the RPE65-deficient dog. Invest Ophthalmol Vis Sci 2011; 52: 1.
63. Li A, Zhu X, Brown B, Craft CM. Gene expression networks underlying retinoic acid-induced differentiation of human retinoblastoma cells. Invest Ophthalmol Vis Sci 2003; 44: 996-1007. (Pubitemid 36297812)